文献速递肝病消化道出血消化内镜

肝硬化患者经皮冠状动脉介入治疗后的临床结局:多中心全国性研究

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study.
PubMed 文献 · Aliment Pharmacol Ther · 2026-08-05

本研究基于TriNetX美国协作网络2015至2024年数据,回顾性分析肝硬化患者接受PCI后的结局。3351例肝硬化患者与对照1:1倾向评分匹配后,肝硬化与更高的1年消化道出血(16.14% vs. 8.12%)和死亡率(13.97% vs. 10.41%)相关。30天标志分析显示,抗血小板单药治疗较双联抗血小板治疗(DAPT)降低1年消化道出血和死亡率,且不增加支架内再狭窄。

要点

  • 肝硬化患者PCI后1年消化道出血和死亡风险显著高于无肝硬化者。
  • 失代偿期肝硬化出血和死亡风险高于代偿期,酒精性肝硬化出血风险高于MASLD肝硬化。
  • PCI后30天改用抗血小板单药治疗可减少出血和死亡,不增加支架再狭窄。

核心结论

  • 肝硬化患者PCI后出血和死亡风险显著增高,尤其失代偿期肝硬化。
  • PCI后30天抗血小板单药治疗与更少出血和更好生存相关,支持缩短DAPT疗程。

研究设计与样本

  • 回顾性队列研究,使用TriNetX美国协作网络2015至2024年数据。
  • 成人接受PCI者按肝硬化状态分层,1:1倾向评分匹配调整人口学和合并症。
  • 匹配后肝硬化组3351例与对照组比较,结局包括消化道出血、缺血事件和全因死亡。

主要发现

  • 肝硬化组1年消化道出血16.14% vs. 对照组8.12%(p < 0.0001)。
  • 肝硬化组1年死亡率13.97% vs. 对照组10.41%(p < 0.0001)。
  • 失代偿期肝硬化出血和死亡高于代偿期;酒精性肝硬化出血高于MASLD肝硬化。
  • 30天标志分析中,抗血小板单药组1年消化道出血10.31% vs. DAPT组20.77%(p < 0.0001)。
  • 抗血小板单药组1年死亡率9.46% vs. DAPT组12.89%(p = 0.04),支架再狭窄无增加。

临床怎么用

  • 肝硬化患者PCI后应警惕高出血和死亡风险,尤其失代偿期患者。
  • PCI后30天考虑抗血小板单药治疗(阿司匹林或P2Y12抑制剂)以降低出血和死亡。
  • 酒精性肝硬化患者PCI后出血风险更高,需加强监测。

局限性

  • 回顾性研究设计,可能存在未测量混杂。
  • 数据来源于TriNetX美国协作网络,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronary artery disease (CAD) is common in cirrhosis patients because of shared risk factors, including metabolic syndrome and alcohol use; however, outcomes after percutaneous coronary intervention (PCI) remain poorly defined. AIMS: To evaluate outcomes after PCI in patients with cirrhosis. METHODS: We conducted a retrospective cohort study using TriNetX US Collaborative Network data from 2015 to 2024. Adults undergoing PCI were stratified by cirrhosis status, with outcomes including gastrointestinal bleeding, ischaemic events, and all-cause mortality. Within the cirrhosis cohort, we evaluated effect modification by aetiology, disease severity, and antiplatelet strategy at 30 days after PCI. One-to-one propensity score matching adjusted for demographics and comorbidities, with results reported as relative risks and 95% confidence intervals. RESULTS: Among 3351 patients with cirrhosis undergoing PCI matched 1:1 to controls, cirrhosis was associated with higher 1-year gastrointestinal bleeding (16.14% vs. 8.12%; p < 0.0001) and mortality (13.97% vs. 10.41%; p < 0.0001). Decompensated cirrhosis had higher gastrointestinal bleeding and mortality than compensated disease, while alcohol-associated cirrhosis had higher gastrointestinal bleeding than metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis. In a 30-day landmark analysis, antiplatelet monotherapy (aspirin or P2Y12 inhibitors) had lower 1-year gastrointestinal bleeding (10.31% vs. 20.77%; p < 0.0001) and mortality (9.46% vs. 12.89%; p = 0.04) without increased stent restenosis compared with dual antiplatelet therapy (DAPT). CONCLUSION: Cirrhosis confers substantially higher bleeding and mortality after PCI, particularly in decompensated disease. Antiplatelet monotherapy after 30 days was associated with less bleeding and improved survival, supporting abbreviated DAPT in this high-risk group.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Gala D, Rao S, Gunani M, et al. Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study. Aliment Pharmacol Ther. 2026. PMID: 42554421. doi:10.1111/apt.70896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。